<DOC>
	<DOCNO>NCT00125021</DOCNO>
	<brief_summary>This phase II trial design investigate effectiveness Tarceva ( OSI-774 ) combine capecitabine treating patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Tarceva Capecitabine Pancreatic Cancer</brief_title>
	<detailed_description>Patients treat daily Tarceva , twice daily capecitabine 14 consecutive day , follow 7 day capecitabine ( cycle 21 day ) . At week 1 cycle physical exam blood work perform . Reassessment tumor size conduct 6 week ( 2 cycle ) , 12 week ( 4 cycle ) every 9 week thereafter . Patients remain treatment one follow occur : disease progression , illness prevents treatment unacceptable adverse event .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Metastatic pancreatic carcinoma ( exclude pancreatic endocrine tumor ) Only patient measurable disease ECOG performance status &lt; equal 1 Life expectancy &gt; 12 week Signed informed consent Failed intolerance firstline therapy metastatic disease gemcitabinecontaining regimen . Patients may receive adjuvant therapy addition one prior regimen metastatic disease . &gt; 4 week must elapse completion previous chemotherapy patient must recover related toxicity &gt; 4 week must elapse participation investigational drug study Laboratory value : ANC &gt; 1500/mm3 ; Hemoglobin &gt; 9.0 gm/dl ; Platelets &gt; 100,000/mm3 ; SGOT &lt; 2.5 X upper limit normal ; &lt; 5 X upper limit normal evidence liver metastasis ; Alkaline phosphatase &lt; 2.5 X upper limit normal ; &lt; 5 X upper limit normal evidence liver metastasis ; Total bilirubin &lt; 1.5 X upper limit normal ; Creatinine clearance &gt; 50 cc/min ( Cockroft Gault determine 24hour urine collection ) . Prior therapy capecitabine epidermal growth factor receptor ( EGFR ) inhibitor More one prior chemotherapy treatment regimen metastatic disease Clinically apparent central nervous system ( CNS ) metastases carcinomatous meningitis Clinically significant cardiac disease ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well control medication heart attack within last 12 month ) . Major surgery within 4 week start study treatment , without complete recovery . Evidence CNS metastasis ( unless CNS metastases stable &gt; 3 month ) history uncontrolled seizure , central nervous system disorder Uncontrolled serious medical psychiatric illness Women must pregnant lactate Concurrent radiation therapy Other active malignancy Inability swallow tablet Patients lack physical integrity upper gastrointestinal tract malabsorption syndrome Prior unanticipated severe reaction fluoropyrimidine therapy , know sensitivity 5fluorouracil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Second Line Therapy</keyword>
	<keyword>Gemcitabine Refractory</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Tarceva</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Metastatic Pancreatic Cancer</keyword>
</DOC>